GET DAILY SIGNALSMyriad Genetics (MYGN) Posts Q3 Revenue Beat While Advancing Strategic Reset
Key Takeaways
- Third quarter 2026 revenue came in at $202.7 million, down 1% year over year but ahead of the S&P consensus estimate of roughly $191 million.
- Adjusted loss per share of $0.11 beat the consensus estimate of about -$0.20, while GAAP net loss widened to $43.9 million, or $0.46 per share.
- Myriad Genetics raised the midpoint of its full-year 2026 revenue guidance to $785 million, with a range of $780 million to $790 million.
- The company agreed to sell its Prenatal Health business to Labcorp for $210 million in cash, refocusing on the Cancer Care Continuum and Mental Health.
- Adjusted EBITDA was a loss of $5.3 million, improving sequentially from the prior quarter.
Earnings Context and Why It Matters
Myriad Genetics quarterly results carry extra significance right now as the company executes a strategic reset. Management is sharpening its focus on the Cancer Care Continuum, which includes hereditary cancer risk testing, treatment selection, and residual disease monitoring, while exiting the declining Prenatal Health segment. The quarter also served as a test of the durability of the recovery following a challenging second quarter. I was watching for evidence that improved payer engagement and revenue cycle work were lifting revenue per test, along with clearer signals on the path to profitability.
Reported Results
For the third quarter ended September 30, 2026, Myriad Genetics posted revenue of $202.7 million. That marked a 6% sequential increase yet a 1% year-over-year decline, still topping the S&P consensus of roughly $191 million. Adjusted loss per share narrowed to $0.11 versus the expected loss of about $0.20. GAAP net loss widened to $43.9 million, or $0.46 per share, from $27.4 million, or $0.29 per share, a year earlier.
Segment performance was mixed. Cancer Care Continuum revenue edged up 1% to $123.9 million, and Mental Health revenue rose 2% to $39.5 million. Prenatal Health revenue fell 12% to $39.3 million, consistent with the planned divestiture. Gross margin slipped 200 basis points to 67.9%, and the operating loss expanded to $39.9 million. Management lifted the midpoint of full-year 2026 revenue guidance to $785 million within a $780 million to $790 million range. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Shares rose roughly 10.7% in after-hours trading to about $6.66 on the report. The positive response reflected the revenue beat, narrower adjusted loss, and added clarity from the Prenatal Health divestiture. Sequential improvement in average revenue per test also helped, which management linked to early gains from payer engagement and revenue cycle initiatives. That said, the company remains unprofitable on a GAAP basis, and hereditary cancer testing revenue still faces reimbursement pressure, so some caution remains warranted.
Forward Outlook and Key Factors to Monitor
The sale of the Prenatal Health business to Labcorp stands out as the central catalyst ahead. The deal is slated to close by early 2027 and should lift revenue growth rates, gross margins, and liquidity. Updates on the timing and deployment of the $210 million in proceeds will be worth tracking, whether directed toward debt reduction, growth investments, or other corporate uses.
Reimbursement trends remain a key variable. Hereditary cancer testing volume grew 6% year over year, yet average revenue per test remained below prior-year levels, with management guiding to a medium-to-long-term annual decline of roughly 1% to 5%. Progress on revenue cycle initiatives and payer-specific market access efforts will serve as important indicators of execution.
The Precise MRD test represents a longer-term growth opportunity. Management expects breast cancer reimbursement to begin in the first half of 2027, followed by colorectal and renal cancer coverage later in the year. Until then, testing demand will be managed carefully, making upcoming reimbursement milestones and clinical data readouts important markers for the story.
Exploring AI Tools for Stock Analysis
In my own workflow, I regularly use Tickeron’s AI Screener to quickly filter opportunities across industries and technical setups. It helps surface names that align with specific criteria like revenue trends or volatility patterns, which can complement traditional fundamental review. The tool is straightforward for scanning thousands of stocks and ETFs without manual effort. Explore it at https://tickeron.com/app-ng/screener/stocks/diy/industries if you are looking to refine your own research process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MYGN's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for MYGN turned positive on October 20, 2026. Looking at past instances where MYGN's MACD turned positive, the stock continued to rise in 28 of 38 cases over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on MYGN as a result. In 63 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
Following a +6.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where MYGN advanced for three days, in 201 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
The Aroon Indicator entered an Uptrend today. In 111 of 160 cases where MYGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Bearish Trend Analysis
The 10-day RSI Indicator for MYGN moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 21 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 54 cases where MYGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
MYGN broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. MYGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.895) is normal, around the industry mean (66.911). P/E Ratio (-5.102) is within average values for comparable stocks, (2.514). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.448) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic and predictive medicine products
Industry MedicalSpecialties
Advertisement